The drug is being evaluated as an oral treatment to reduce the frequency and severity of allergic reactions following exposure to peanuts in children and adolescents ages 4 to 17.
A biologics license application for the drug is under review by the US Food and Drug Administration and is expected to take until late January. The allergenic products advisory committee of the FDA will review the application at its Sept. 13 meeting.
Price: 19.92, Change: +0.30, Percent Change: +1.53
|Copart (CPRT) Insider Makes Significant Share Sale|
|Insider at Aptinyx (APTX) Makes Significant purchase...|
|Insiders Make Significant Stock Sales in PriceSmart ...|
|Significant Insider Selling Reported in Shares of Ap...|
|Insiders Make Significant Stock Sales in Goosehead I...|